Article Sidebar
Published:
Feb 11, 2025Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Protective effect of saroglitazar against sepsis-induced acute kidney injury in rats
Abstract
Purpose: To assess the effect of saroglitazar (a dual-acting peroxisome proliferator-activated receptor alpha (PPAR-α/γ) agonist in sepsis-induced acute kidney injury (S-AKI) using a rat model. Methods: Female Wistar albino rats were divided into control (n = 12), and study group (n = 24; further divided into groups 1 and 2; n = 12 each) following cecal ligation and puncture (CLP) procedure. Control group received normal saline while study group 1 received normal saline and study group 2 received saroglitazar (2 mg/kg/day) intraperitoneally (IP) twice daily for 5 days. Biochemical markers (malondialdehyde (MDA), neutrophil extracellular traps (NETs), insulin-like growth factor (IGF) binding protein 7 (IGFBP-7), blood urea nitrogen (BUN), creatinine, and nod-like receptor protein 3 (NLRP3), neurolopin-1), histopathology of kidney, as well as enzyme-linked immunosorbent assay (ELISA) were employed to evaluate renal injury and therapeutic effects. Results: Saroglitazar significantly reduced MDA, TNF-α, NETs, IGFBP-7, BUN, creatinine, NLRP3 and neuropilin-1 (p < 0.05) compared to control group. Histopathological analysis revealed significantly reduced tubular injury and inflammation in the study group compared to control group (p < 0.01) Conclusion: Saroglitazar demonstrates protective and therapeutic effects against S-AKI in rats by reducing inflammation, oxidative stress, and cellular damage. Early saroglitazar use in septic patients may be beneficial, and further clinical studies are warranted to establish its efficacy and safety in managing S-AKI.
